Active Biotech (Sweden) Insiders
| ACTI Stock | SEK 0.12 0.01 9.09% |
Active Biotech employs about 9 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 3.0 employees per reported executive. Breaking down Active Biotech's management performance can provide insight into the firm performance.
| Helen Tuvesson Executive Chief Scientific Officer |
| Hans Kolam Executive Chief Officer |
Active |
Active Biotech Management Team Effectiveness
The company has return on total asset (ROA) of (0.6714) % which means that it has lost $0.6714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4389) %, meaning that it generated substantial loss on money invested by shareholders. Active Biotech's management efficiency ratios could be used to measure how well Active Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Active Biotech Workforce Comparison
Active Biotech AB is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,897. Active Biotech adds roughly 9.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Active Biotech AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Active Biotech AB Price Series Summation is a cross summation of Active Biotech price series and its benchmark/peer.
Active Biotech Notable Stakeholders
An Active Biotech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Active Biotech often face trade-offs trying to please all of them. Active Biotech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Active Biotech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Helen Tuvesson | Chief Scientific Officer | Profile | |
| Hans Kolam | Chief Officer | Profile | |
| Erik Vahtola | Chief Officer | Profile |
About Active Biotech Management Performance
The success or failure of an entity such as Active Biotech AB often depends on how effective the management is. Active Biotech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Active management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Active management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Active Biotech AB , a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunityinflammatory, and cancer. Active Biotech AB was incorporated in 1982 and is based in Lund, Sweden. Active Biotech operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.
Please note, the imprecision that can be found in Active Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Active Biotech AB. Check Active Biotech's Beneish M Score to see the likelihood of Active Biotech's management manipulating its earnings.
Active Biotech Workforce Analysis
Traditionally, organizations such as Active Biotech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Active Biotech within its industry.Active Biotech Manpower Efficiency
Return on Active Biotech Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.5M | |
| Net Loss Per Executive | 16.6M | |
| Working Capital Per Employee | 4M | |
| Working Capital Per Executive | 12M |
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.